Cargando…

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer

BACKGROUND: This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐angiogenesi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Li‐Yue, Cen, Wen‐Jian, Tang, Wen‐Ting, Long, Ya‐Kang, Yang, Xin‐Hua, Ji, Xiao‐Meng, Yang, Jiao‐Jiao, Zhang, Ren‐Jing, Wang, Fang, Shao, Jian‐Yong, Du, Zi‐Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495280/ https://www.ncbi.nlm.nih.gov/pubmed/34469045 http://dx.doi.org/10.1002/cam4.4197

Ejemplares similares

Prediction of prognosis of patients with lung cancer in combination with the immune score
por: Han, Ke, et al.
Publicado: (2021)

Blood prognostic predictors of treatment response for patients with papillary thyroid cancer
por: Liu, Xiangxiang, et al.
Publicado: (2020)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition
por: von Reibnitz, Donata, et al.
Publicado: (2018)

Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis
por: He, Cai‐Yun, et al.
Publicado: (2020)

Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
por: Alhalabi, Omar, et al.
Publicado: (2023)

Combination of lysine‐specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer
por: Chen, Xiaying, et al.
Publicado: (2020)

Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy
por: Sun, Li-Yue, et al.
Publicado: (2022)

PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer
por: Zhang, Min, et al.
Publicado: (2020)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

A systematic investigation of the association between HPV and the clinicopathological parameters and prognosis of oral and oropharyngeal squamous cell carcinomas
por: Wang, Fengze, et al.
Publicado: (2017)

Tumor burden score dictates prognosis of patients with combined hepatocellular cholangiocarcinoma undergoing hepatectomy
por: Deng, Gang, et al.
Publicado: (2023)

Marital status and survival in patients with gastric cancer
por: Jin, Jie‐Jie, et al.
Publicado: (2016)

Novel immune–risk score of gastric cancer: A molecular prediction model combining the value of immune–risk status and chemosensitivity
por: Duan, Shijie, et al.
Publicado: (2019)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

Relationship between red cell distribution width and prognosis of patients with osteosarcoma
por: Zheng, Jian, et al.
Publicado: (2019)

Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma
por: Wang, Jian‐Hua, et al.
Publicado: (2019)

Epstein–Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma
por: Xia, Bing, et al.
Publicado: (2019)

Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma
por: Qiu, Miao‐Zhen, et al.
Publicado: (2021)

Association between the combined effects of GSTM1 present/null and CYP1A1 MspI polymorphisms with lung cancer risk: an updated meta-analysis
por: Zhang, Wen-Ping, et al.
Publicado: (2020)

Ryanodine receptor (RYR) mutational status correlates with tumor mutational burden, age and smoking status and stratifies non-small cell lung cancer patient prognosis
por: Wang, Yang, et al.
Publicado: (2022)

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
por: Fransen van de Putte, Elisabeth E., et al.
Publicado: (2023)

Individual and combined effects of GSTM1 and GSTT1 polymorphisms on colorectal cancer risk: an updated meta-analysis
por: Song, Liang, et al.
Publicado: (2020)

Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular‐cholangiocarcinoma after resection
por: Song, Peipei, et al.
Publicado: (2019)

Methionine deficiency facilitates antitumour immunity by altering m(6)A methylation of immune checkpoint transcripts
por: Li, Ting, et al.
Publicado: (2023)

Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer
por: Rossetti, Rafaela, et al.
Publicado: (2022)

Associations of reproductive factors with breast cancer prognosis and the modifying effects of menopausal status
por: Zhang, Jia‐Yi, et al.
Publicado: (2019)

Clinical effects of Chemotherapy combined with Immunotherapy in patients with advanced NSCLC and the effect on their nutritional status and immune function
por: Jiao, Jin, et al.
Publicado: (2023)

A three‐gene signature from protein–protein interaction network of LOXL2‐ and actin‐related proteins for esophageal squamous cell carcinoma prognosis
por: Zhan, Xiu‐hui, et al.
Publicado: (2017)

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer
por: Qin, Angel, et al.
Publicado: (2016)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

In utero and early-life exposure to thirdhand smoke causes profound changes to the immune system
por: Snijders, Antoine M., et al.
Publicado: (2021)

Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma
por: Hennessy, Marlene, et al.
Publicado: (2020)

Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma
por: van Gulijk, Mandy, et al.
Publicado: (2022)

Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
por: Delahousse, Julia, et al.
Publicado: (2020)

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
por: Palmer, Adam C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m3ahorqhovocda53bou0oh56aj